about
Structure of the α-tubulin acetyltransferase, αTAT1, and implications for tubulin-specific acetylationHistone deacetylases (HDACs): characterization of the classical HDAC familyNicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotauPhase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Epigenetic: A missing paradigm in cellular and molecular pathways of sulfur mustard lung: a prospective and comparative studyA perspective on dietary phytochemicals and cancer chemoprevention: oxidative stress, nrf2, and epigenomicsStructure and mechanism of non-histone protein acetyltransferase enzymesIncreased production of interleukin-8 in primary human monocytes and in human epithelial and endothelial cell lines after dengue virus challengeStructure of the GCN5 histone acetyltransferase bound to a bisubstrate inhibitorPhosphorylation of Ser28 in histone H3 mediated by mixed lineage kinase-like mitogen-activated protein triple kinase alphaUnique anti-glioblastoma activities of hypericin are at the crossroad of biochemical and epigenetic events and culminate in tumor cell differentiationHistone acetyltransferase MOZ acts as a co-activator of Nrf2-MafK and induces tumour marker gene expression during hepatocarcinogenesisAlzheimer disease pathology in cognitively healthy elderly: a genome-wide studyStructure of Patt1 human proapoptotic histone acetyltransferaseHigh class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo.Role of accessory proteins of HTLV-1 in viral replication, T cell activation, and cellular gene expression.N-lysine propionylation controls the activity of propionyl-CoA synthetase.Investigation of MYST4 histone acetyltransferase and its involvement in mammalian gametogenesisEvaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial.Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma.Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara studyPurification and characterization of recombinant CH3 domain fragment of the CREB-binding protein.The role of cullin4B in human cancers.Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1.Ethylene induces combinatorial effects of histone H3 acetylation in gene expression in Arabidopsis.Jmjd3-mediated epigenetic regulation of inflammatory cytokine gene expression in serum amyloid A-stimulated macrophages.Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines.Regulating histone acetyltransferases and deacetylases.Investigation of the acetylation mechanism by GCN5 histone acetyltransferase.Histone modification enzymes: novel targets for cancer drugs.Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.Molecular modeling study on tunnel behavior in different histone deacetylase isoforms.Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics.Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours.Histone deacetylase inhibitors: from target to clinical trials.Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death.Histone deacetylase inhibitors in clinical development.Mitochondrial DNA variants can mediate methylation status of inflammation, angiogenesis and signaling genes.Relevance of systems biological approach in the differential diagnosis of invasive lobular carcinoma & invasive ductal carcinomaVorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects.
P2860
Q24300995-9A1E20A6-4DEA-4525-91B2-530BCB7BB7E7Q24535587-23C9F986-9839-457C-8091-B1527D2662C4Q24651880-30499CEE-C3D3-4A99-9698-82AD2EE33B09Q24681480-AC3C17FC-C56A-4979-846D-5D6AE492D411Q26777648-4AEB593D-07FC-49BA-9B2A-A6585A661BA4Q26852571-A9104D2F-0681-4473-B6BF-B2EAE70E3185Q26996044-8FD0BEF3-5A7E-4B79-882F-9E5022DD12C6Q27472957-B80234D8-A46A-4624-BA19-44FD58C07F6AQ27639868-C26075B8-1274-483E-8C12-BC49552BDC4AQ28305184-4C3AFF1D-9794-4E6D-9145-A869826EF492Q28533490-4A44056D-C14E-434A-9DB3-E9AB30BFB67BQ28574325-29FE77B3-59A7-4996-9990-F0A38FFFA88EQ28943540-57BD1AD1-E95B-4DE4-A7B7-181605320B5CQ30355728-7ACDE04F-B148-4875-878E-453C0FB3205FQ30884835-F140A31B-5B09-4548-AE21-455286A441A1Q33206633-18817ED3-681B-4F66-AE0B-69A35300390AQ33293490-80B24B18-D691-4158-8F82-307362EE373AQ33304887-B5B5C4EC-B665-45CB-9D49-6A94167A257CQ33399121-31E83E88-C063-41A9-A174-3C5527651A64Q33400756-CE302F04-4FBB-4D4C-B913-3783FBC11B71Q33424306-DD928184-969F-43FF-ADC3-CCA5F7036B19Q33738185-FAE8E82A-F0C4-4F70-9717-DAF72E9B52C6Q33802187-154AE22B-CE55-4DCD-80D1-168176C6896EQ33862991-98CB4D17-D46B-4E1B-BCB0-01B8F1E8D378Q33909139-1EFD85BA-8819-4ACD-88E2-7EA6E74DF04BQ33922619-8209D1BF-BA3F-48A0-BE63-287717232487Q34160419-BD98F06A-EB31-4354-84A7-D984B15D1257Q34250532-147567BE-7F9C-4D95-A15D-D6B7D34B9468Q34264881-66A3E7B6-0B7C-4828-9CBF-A1584BE23B95Q34322087-8E6A7CF3-4166-4104-B054-DE7C58FDEE7EQ34371357-693AC550-ED3C-4322-9623-D915B6D9042AQ34499630-A6512FFA-CCDA-4A1E-B3D5-7362AF74915AQ34554335-9BC97079-15C5-40B6-88C2-E404C127AF16Q34621838-6AE01C1D-4674-427D-942B-BC21B2A6EF3CQ35011880-7B5DDAFB-2FA1-42B5-A60A-33686CC09AB3Q35183027-CE75BA7B-7C7D-470B-BB57-3FD07E1E0D7BQ35609717-007B506D-B2D5-487D-B03D-D673F274BB63Q35882554-B7EB5BA8-C0D2-4979-AEF6-BC5E666BC003Q35939577-B1186B0C-E289-44FC-976C-5DD63A85835FQ35939690-90190A8C-C757-4F59-9948-DD49E4A9917A
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Histone acetylation and disease.
@ast
Histone acetylation and disease.
@en
Histone acetylation and disease.
@nl
type
label
Histone acetylation and disease.
@ast
Histone acetylation and disease.
@en
Histone acetylation and disease.
@nl
prefLabel
Histone acetylation and disease.
@ast
Histone acetylation and disease.
@en
Histone acetylation and disease.
@nl
P2093
P356
P1476
Histone acetylation and disease.
@en
P2093
A Harel-Bellan
A Polesskaya
H Lehrmann
S Timmermann
P2888
P304
P356
10.1007/PL00000896
P577
2001-05-01T00:00:00Z